First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation

International Journal of Radiation Oncology Biology Physics - Netherlands
doi 10.1016/j.ijrobp.2019.06.2305
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma

Archives of Neurology
2010English

BMX-001, a Novel Redox-Active Metalloporphyrin, Improves Islet Function and Engraftment in a Murine Transplant Model

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2018English

The Information and Support Needs of Patients Diagnosed With High Grade Glioma

Patient Education and Counseling
Medicine
2010English

Clinical Significance of FBXO17 Gene Expression in High-Grade Glioma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

International Differences in Treatment and Clinical Outcomes for High Grade Glioma

PLoS ONE
Multidisciplinary
2015English

403. Toca Retroviral Replicating Vector in Tumor and Blood From Clinical Trial Subjects With Recurrent High Grade Glioma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

Yoga Program for High-Grade Glioma Patients Undergoing Radiotherapy and Their Family Caregivers

Integrative Cancer Therapies
OncologyAlternative MedicineComplementary
2017English

Benefit of Continuous Treatment for Responders With Newly Diagnosed Multiple Myeloma in the Randomized FIRST Trial

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

Prognostic Value of the S100B Protein in Newly Diagnosed and Recurrent Glioma Patients: A Serial Analysis

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy